Resumen

MARQUES, Rita et al. The use of infliximab in a pediatric gastroenterology consultation. J Port Gastrenterol. [online]. 2012, vol.19, n.3, pp.126-129. ISSN 0872-8178.

Introduction: Infliximab is a monoclonal antibody used in refractory inflammatory bowel disease (IBD). Aim: To evaluate the clinical response and adverse effects of infliximab therapy in paediatric IBD patients. Methods: Analytic, descriptive and cross sectional study of Outpatient Clinic of Pediatric Gastroenterology treated with infliximab. Results: Of six patients treated with infliximab, five have moderate to severe Crohn’s disease and one present Ulcerative Colitis. There was clinical remission in five patients. Resolution in analytical changes was observed after 6 months of therapy. There were two mild allergic reactions and a transient elevation of transaminases. Conclusions: In accordance with the literature, in our population, infliximab therapy has been well tolerated and effective in disease control.

Palabras clave : Infliximab; Inflammatory bowel disease; Pediatric.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )